Moreover, the potential of the lectin as a novel target in PDA cannot be underestimated, considering that PDA development in a Gal-1 knockout background is significantly delayed [24, 25], and that its inhibition (using peptides, glycan-based inhibitors or more specific monoclonal antibodies) has a proven efficacy for other tumors [19, 53–60]. Here, LGALS1 is linked to Patent ductus arteriosus.